Persons using assistive technology might not be able to fully access information in this file. For assistance, please send e-mail to: mmwrq@cdc.gov. Type 508 Accommodation and the title of the report in the subject line of e-mail.
Notice to Readers: FDA Approval for a Combined Hepatitis A and B Vaccine
On May 11, 2001, the Food and Drug Administration (FDA) licensed a
combined hepatitis A and B vaccine
(Twinrix®) for use in persons aged
>18 years. Twinrix is manufactured and distributed by GlaxoSmithKline Biologicals (Rixensart,
Belgium), and is made of the antigenic components used in Havrix and
Engerix-B (GlaxoSmithKline). The antigenic components in Twinrix have been used routinely
in separate single antigen vaccines in the United States since 1995 and 1989 as
hepatitis A and B vaccines, respectively.
Vaccine Description
Each dose of Twinrix contains at least 720 enzyme-linked immunosorbent
assays units of inactivated hepatitis A virus and 20 mcg of recombinant hepatitis B
surface antigen (HBsAg) protein, with 0.45 mg of aluminum in the form of aluminum
hydroxide and aluminum phosphate as adjuvants, 5.0 mg 2-phenoxyethanol as a
preservative, and pH stabilizer in normal saline. Trace amounts of thimerosal (<1
µg mercury), neomycin (<20 ng), formalin
(<0.1 mg), and yeast protein
(<5%) also are present from the manufacturing process.
Indications and Usage
Twinrix is indicated for vaccination of persons aged
>18 years against hepatitis A and B. Any person in this age group having an indication for both hepatitis A and
B vaccination can be administered Twinrix, including patients with chronic liver
disease, users of illicit injectable drugs, men who have sex with men, and persons with
clotting factor disorders who receive therapeutic blood products
(1,2). For international travel, hepatitis A vaccine is recommended for travelers to areas of high or
intermediate hepatitis A endemicity; hepatitis B vaccine is recommended for travelers to areas
of high or intermediate hepatitis B endemicity who plan to stay for
>6 months and have frequent close contact with the local population
(3). Primary vaccination consists of three doses, given on a 0-, 1-, and 6-month schedule, the same schedule as that
used for single antigen hepatitis B vaccine.
Safety and Immunogenicity
Adverse experiences (AEs) were evaluated in clinical trials in which 6594 doses
of Twinrix were administered to 2165 persons. Observed AEs generally were similar
in type and frequency to those observed after vaccination with monovalent hepatitis
A and B vaccines. The frequency of AEs did not increase with subsequent doses
of Twinrix. No serious vaccine-related AEs were observed (GlaxoSmithKline
Biologicals, unpublished data, 2001). Twinrix is contraindicated in persons with
known
hypersensitivity to any component of the vaccine.
Prelicensure clinical trials indicate that the immunogenicity of Twinrix is
equivalent to that of the single antigen hepatitis vaccines. Data from 11 clinical trials that
included adults aged 17--70 years indicated, 1 month after completion of the three dose
series, seroconversion for antibodies against hepatitis A virus (anti-HAV titer
>20 mIU/mL or 33mIU/mL [Enzymun-Test, Boehringer Mannheim Immunodiagnostics,
Mannheim, Germany]) were elicited in 99.9% of vaccinees, and protective antibodies
against HBsAg (anti-HBs >10 mIU/mL [AUSAB, Abbott Laboratories, Abbott Park,
Illinois]) were elicited in 98.5% of vaccinees. One month after one dose of
Twinrix, seroconversion to anti-HAV was seen in 93.8% of vaccinees and protective
anti-HBs concentrations in 30.8%. One month after the second dose, seroconversion to
anti-HAV was seen in 98.8% of vaccinees, and protective anti-HBs concentrations in
78.2%. The efficacy of Twinrix is expected to be comparable with existing single
antigen hepatitis vaccines. The persistence of anti-HAV and anti-HBs following
Twinrix administration is similar to that following single antigen hepatitis A and B
vaccine administration at 4 years follow-up (GlaxoSmithKline Biologicals, unpublished
data, 2001). Additional information is available from the manufacturer's package insert
and GlaxoSmithKline Vaccines, telephone (800) 366-8900.
CDC. Health information for international travel 2001--2002. Atlanta, Georgia:
US Department of Health and Human Services, Public Health Service, CDC, 2001.
Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of
Health and Human Services.
References to non-CDC sites on the Internet are
provided as a service to MMWR readers and do not constitute or imply
endorsement of these organizations or their programs by CDC or the U.S.
Department of Health and Human Services. CDC is not responsible for the content
of pages found at these sites.
Disclaimer
All MMWR HTML versions of articles are electronic conversions from ASCII text
into HTML. This conversion may have resulted in character translation or format errors in the HTML version.
Users should not rely on this HTML document, but are referred to the electronic PDF version and/or
the original MMWR paper copy for the official text, figures, and tables.
An original paper copy of this issue can be obtained from the Superintendent of Documents,
U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800.
Contact GPO for current prices.
**Questions or messages regarding errors in formatting should be addressed to
mmwrq@cdc.gov.
